ADMS stock forecast
Our latest prediction for Adamas Pharmaceuticals, Inc.'s stock price was made on the Jan. 21, 2020 when the stock price was at 5.97$.
In the short term (2weeks), ADMS's stock price should underperform the market by -1.94%. During that period the price should oscillate between -10.54% and +16.25%.
In the medium term (3months), ADMS's stock price should underperform the market by -9.95%. During that period the price should oscillate between -40.91% and +31.31%.Get email alerts
Create a solid portfolio with ADMS
About Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
At the moment the company generates 52M USD in revenues.
On its last earning announcement, the company reported a loss of -4.01$ per share.
The book value per share is 5.24$
Three months stock forecastJan. 21, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|